Indivior Pharmaceuticals Inc (INDV) Stock AnalysisINDVStock AnalysisIndivior Pharmaceuticals Inc

Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Indivior PLC appears to be a good buy right now due to its current price of $34.87, which is significantly below the analyst price target of $53 from Craig-Hallum, indicating a potential upside of 52%. Additionally, the forward P/E ratio of 9.69 suggests that the stock is undervalued compared to its earnings potential. The main risk is the recent 5-day price change of -5.42%, which indicates short-term volatility, but the long-term outlook remains positive due to the merger with Supernus and expected cost synergies of $125 million annually.